Guillén G, Aguilar LC, Dueñas S, Hermida L, Iglesias E, Muzio V, Pentón E, Mussacchio A, González LJ, Guzmán G, Lobaina Y, Amador Y, Reyes O, Lazo L, Aguilar A, Palenzuela D, Cabrales A, Gil L, Pichardo D, Valdés I, Marcos E, Cosme K, Herrera L

Idioma: Ingles.
Referencias bibliográficas: 12
Paginas: 183-185
Archivo PDF: 144.21 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Aguilar JC, Lobaina Y, Muzio V, García D, Pentón E, Iglesias E, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol. 2004; 82: 539-546.

2. Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillén G, Aguilar JC. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol. 2005; 42(3):289-94.

3. Guillén G, Aguilar JC, Dueñas S, Hermida L, Guzmán MG, Pentón E, et al. Virus-Like Particles as vaccine antigens and adjuvants: application to chronic disease, cancer immunotherapy and infectious disease preventive strategies. Procedia Vaccinol. 2010;2(2):128-33.

4. Iglesias E, Aguilar JC, Cruz LJ, Reyes O. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg. Mol Immunol. 2005;42(1):99-104.

5. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.

6. Lazo L, Gil L, Lopez C, Valdes I, Marcos E, Alvarez M, et al. Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Arch Virol. 2010;155(10):1587-95.

7. Aguilar A, González CA, Cinza Z, Cabrera J, Véliz G, Moreno SR, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis. 2007;11(5):394-401.

8. Acosta-Rivero N, Rodriguez A, Mussachio A, Poutou J, Falcon V, Torres D, et al. A C-terminal truncated hepatitis C virus core protein variant assembles in vitro into virus-like particles in the absence of structured nucleic acids. Biochem Biophys Res Commun. 2005;334(3):901-6.

9. Bacardí D, Amador-Cañizares Y, Cosme K, Urquiza D, Suárez J, Marante J, et al. Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus. Hum Exp Toxicol. 2009;28(8): 479-91.

10. Cruz LJ, Iglesias E, Aguilar JC, González LJ, Reyes O, Albericio F, et al. A comparative study of different presentation strategies for an HIV peptide immunogen. Bioconjug Chem. 2004;15(1):112-20.

11. Cruz LJ, Cabrales A, Iglesias E, Aguilar JC, González LJ, Reyes O. Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins. Int Immunol. 2009;9(12):1452-9.

12. Alvarez-Lajonchere L, González M, Alvarez-Obregón JC, Guerra I, Viña A, Acosta-Rivero N, et al. Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice. Biotechnol Appl Biochem. 2006;44(Pt 1): 9-17.